Directory of sitesLoginContactSupport
for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

日本化薬株式会社

4272.T

現在値

1,168.00JPY

変化

--(--)

本日のレンジ

--

 - 

--

52週レンジ

1,075.00

 - 

1,289.00

∙ 約20分前の相場を表示しています。

適時開示

Nippon Kayaku Co Ltd: Bought Back 248,800 Own Shares Worth 297 Million Yen Between March 1 And March 16

March 23 (Reuters) - Nippon Kayaku Co Ltd <4272.T>::NIPPON KAYAKU CO LTD : BOUGHT BACK 248,800 OWN SHARES WORTH 297 MILLION YEN BETWEEN MARCH 1 AND MARCH 16.

Nippon Kayaku Co bought back 933,300 own shares worth 1.1 billion yen in January

Feb 6 (Reuters) - Nippon Kayaku Co Ltd <4272.T>::: BOUGHT BACK 933,300 OWN SHARES WORTH 1.1 BILLION YEN IN JANUARY.

Nippon Kayaku Co Ltd - Bought Back 559,000 Own Shares Worth 659 Million Yen In December

Nippon Kayaku Co Ltd <4272.T>::NIPPON KAYAKU CO LTD - BOUGHT BACK 559,000 OWN SHARES WORTH 659 MILLION YEN IN DECEMBER.

Nippon Kayaku Co Ltd Bought Back 230,000 Own Shares Worth 280 Million Yen In November

Nippon Kayaku Co Ltd <4272.T>::NIPPON KAYAKU CO LTD: BOUGHT BACK 230,000 OWN SHARES WORTH 280 MILLION YEN IN NOVEMBER.

Nippon Kayaku Co Ltd Says To Buy Back Up To 1.78% Of Own Shares Worth 3 Billion Yen

Nippon Kayaku Co Ltd <4272.T>::NIPPON KAYAKU CO LTD SAYS TO BUY BACK UP TO 1.78% OF OWN SHARES WORTH 3 BILLION YEN.

Nippon Kayaku to merge with units

Aug 28(Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says it plans to merge with a wholly owned Hiroshima-based unit and a wholly owned Tokyo-based unit.Merger effective Oct. 1.Says the two units will be dissolved after the merger .

R&I affirms Nippon Kayaku's rating at "A" and says stable outlook-R&I

June 5 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A"-R&I.Rating outlook stable-R&I .

Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit

April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc.

Nippon Kayaku initiates phase II clinical trials on NK105 for treatment of breast cancer

Feb 21 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says it initiated phase II clinical trials on NK105 for treatment of breast cancer .

Nippon Kayaku unit acquires 100 pct stake in RaySpec

Dec 27(Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says its consolidated subsidiary Polatechno Co Ltd <<<4239.T>>> acquired 100 percent stake in the United Kingdom-based firm RaySpec Limited, on Dec. 26.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up